
Last updated: 2026-09-11 05:29:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
GH Research PLC (GHRS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $27.21, with a market capitalization of $1.91B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $11.83 to $31.44. This page covers its latest market performance, valuation, price trends and company information.
$1.91B | |
$27.24 | |
$31.44 | |
$5.05 | |
$27.56 | |
110.03K | |
277.85K | |
-- | |
$31.44 | |
$11.83 | |
-- | |
-- |
GH Research PLC (GHRS) last closed at $27.56 as of 2026-09-10 23:31:00, unchanged from the previous close of $27.56.
During the latest regular trading session, GHRS traded between $5.05 and $31.44, with a volume of 110.03K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, GH Research PLC (GHRS) moved from $26.98 to $27.21, representing a gain of 0.86% ($0.23).
The stock traded between $26.46 and $28.84 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 211.27 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 78.4%
GHRS is currently trading at $27.21, placing it 78.4% of the way from its 52-week low of $11.83 to its 52-week high of $31.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
| Employees | 73 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of GH Research PLC (GHRS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.